GOODWILL AND OTHER INTANGIBLE ASSETS

3 Months Ended

Mar. 31, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

GOODWILL AND OTHER INTANGIBLE ASSETS

6. GOODWILL AND OTHER INTANGIBLE ASSETS

The net carrying value of the identifiable intangible assets from all acquisitions within continuing operations as of March 31, 2023 and December 31, 2022 are as follows:

		As of March 31, 2023			As of December 31, 2022
	Life	Carrying			Carrying
	(Years)	Amount			Amount
Asuragen acquisition:
Thyroid	9	$	8,519		$	8,519
RedPath acquisition:
Pancreas test	7		16,141			16,141
Barrett’s test	9		6,682			6,682
CLIA Lab	2.3		609			609
Total		$	31,951		$	31,951
Accumulated Amortization			(31,407	)		(31,090	)
Net Carrying Value		$	544		$	861

Amortization expense from continuing operations was approximately $0.3 million for both the three-month periods ended March 31, 2023 and 2022, respectively. The remaining amortization expense of $0.5 million will be amortized in 2023.